Case Type: Mergers & Acquisitions

TCR² Therapeutics Inc. (NASDAQ: TCRR), relating to its proposed sale to Adaptimmune Therapeutics plc. Under the terms of the agreement, TCRR shareholders are expected to receive 1.5117 shares of Adaptimmune per share they own.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), relating to its proposed merger with TCR² Therapeutics Inc. Under the terms of the agreement, ADAP shareholders are expected to own approximately 75% of the combined company.

Ranger Oil Corp. (NASDAQ: ROCC), relating to its proposed sale to Baytex Energy Corp. Under the terms of the agreement, ROCC shareholders are expected to receive 7.49 shares of Baytex and $13.31 in cash per share they own.

Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), relating to its proposed merger with DMK Pharmaceuticals Corp.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), relating to its proposed merger with Redx Pharma.

Broadmark Realty Capital Inc. (NYSE: BRMK), relating to its proposed merger with Ready Capital Corp. Under the terms of the agreement, BRMK shareholders are expected to receive 0.47233 shares of Ready Capital stock per share they own.

Focus Financial Partners Inc. (NASDAQ: FOCS), relating to its proposed sale to affiliates of Clayton Dubilier & Rice LLC. Under the terms of the agreement, FOCS shareholders are expected to receive $53.00 in cash per share they own.

Vascular Biogenics Ltd. (NASDAQ: VBLT), relating to its proposed merger with Notable Labs, Inc. Under the terms of the agreement, VBLT shareholders are expected to own approximately 24% of the combined company.

Horizon Technology Finance Management LLC (NASDAQ: HRZN), relating to its proposed sale to an affiliate of Monroe Capital LLC.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), relating to its proposed merger with MEI Pharma, Inc.. Under the terms of the agreement, INFI shareholders are expected to own approximately 42% of the newly combined company.